Sinco Pharmaceuticals Holdings Limited (HKG:6833)
Hong Kong
· Delayed Price · Currency is HKD 0.184
+0.014 (8.24%)
Mar 9, 2026, 2:25 PM HKT
HKG:6833 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 2,490 | 2,821 | 2,540 | 2,272 | 2,024 | 2,050 | Upgrade
|
| Revenue Growth (YoY) | -16.34% | 11.07% | 11.82% | 12.22% | -1.26% | 74.24% | Upgrade
|
| Cost of Revenue | 2,233 | 2,521 | 2,217 | 1,966 | 1,659 | 1,776 | Upgrade
|
| Gross Profit | 257.43 | 299.94 | 323.28 | 305.87 | 364.95 | 273.83 | Upgrade
|
| Selling, General & Admin | 160.13 | 189.92 | 202.58 | 198.44 | 171.38 | 130.39 | Upgrade
|
| Operating Expenses | 162.98 | 186 | 206.82 | 204.64 | 172.4 | 130.04 | Upgrade
|
| Operating Income | 94.45 | 113.95 | 116.46 | 101.22 | 192.55 | 143.79 | Upgrade
|
| Interest Expense | -16.02 | -12.55 | -9.81 | -13.81 | -21.45 | -6.87 | Upgrade
|
| Interest & Investment Income | 2.98 | 6.12 | 5.97 | 2.42 | 1.31 | 1.95 | Upgrade
|
| Currency Exchange Gain (Loss) | -18.8 | -12.6 | -8.64 | 15.98 | -3.55 | -6.06 | Upgrade
|
| Other Non Operating Income (Expenses) | 6.21 | 8.93 | -1.13 | -3.89 | -1.49 | 3.14 | Upgrade
|
| EBT Excluding Unusual Items | 68.82 | 103.84 | 102.85 | 101.93 | 167.39 | 135.96 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.81 | - | 0.04 | - | - | - | Upgrade
|
| Other Unusual Items | -3.14 | -4.92 | -3 | -2.63 | - | - | Upgrade
|
| Pretax Income | 67.48 | 98.92 | 99.88 | 99.29 | 167.39 | 135.96 | Upgrade
|
| Income Tax Expense | 24.92 | 56.88 | 57.53 | 29.83 | 32.3 | 17.82 | Upgrade
|
| Earnings From Continuing Operations | 42.56 | 42.05 | 42.35 | 69.46 | 135.08 | 118.14 | Upgrade
|
| Net Income | 42.56 | 42.05 | 42.35 | 69.46 | 135.08 | 118.14 | Upgrade
|
| Net Income to Common | 42.56 | 42.05 | 42.35 | 69.46 | 135.08 | 118.14 | Upgrade
|
| Net Income Growth | -8.71% | -0.73% | -39.03% | -48.58% | 14.34% | 401.60% | Upgrade
|
| Shares Outstanding (Basic) | 2,033 | 2,033 | 2,033 | 2,032 | 1,737 | 1,692 | Upgrade
|
| Shares Outstanding (Diluted) | 2,033 | 2,033 | 2,033 | 2,032 | 1,737 | 1,692 | Upgrade
|
| Shares Change (YoY) | -0.04% | - | 0.07% | 16.93% | 2.69% | - | Upgrade
|
| EPS (Basic) | 0.02 | 0.02 | 0.02 | 0.03 | 0.08 | 0.07 | Upgrade
|
| EPS (Diluted) | 0.02 | 0.02 | 0.02 | 0.03 | 0.08 | 0.07 | Upgrade
|
| EPS Growth | -8.32% | - | -41.18% | -56.28% | 11.39% | 401.62% | Upgrade
|
| Free Cash Flow | -4.46 | -268.04 | 324.15 | 22.39 | 282.19 | 136.93 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.13 | 0.16 | 0.01 | 0.16 | 0.08 | Upgrade
|
| Dividend Per Share | 0.002 | 0.002 | 0.004 | 0.009 | - | - | Upgrade
|
| Dividend Growth | -46.92% | -46.92% | -59.16% | - | - | - | Upgrade
|
| Gross Margin | 10.34% | 10.63% | 12.73% | 13.46% | 18.03% | 13.36% | Upgrade
|
| Operating Margin | 3.79% | 4.04% | 4.58% | 4.46% | 9.51% | 7.02% | Upgrade
|
| Profit Margin | 1.71% | 1.49% | 1.67% | 3.06% | 6.67% | 5.76% | Upgrade
|
| Free Cash Flow Margin | -0.18% | -9.50% | 12.76% | 0.99% | 13.94% | 6.68% | Upgrade
|
| EBITDA | 117.18 | 132.52 | 127.34 | 109.01 | 197.69 | 152.05 | Upgrade
|
| EBITDA Margin | 4.71% | 4.70% | 5.01% | 4.80% | 9.77% | 7.42% | Upgrade
|
| D&A For EBITDA | 22.73 | 18.58 | 10.88 | 7.79 | 5.14 | 8.26 | Upgrade
|
| EBIT | 94.45 | 113.95 | 116.46 | 101.22 | 192.55 | 143.79 | Upgrade
|
| EBIT Margin | 3.79% | 4.04% | 4.58% | 4.46% | 9.51% | 7.02% | Upgrade
|
| Effective Tax Rate | 36.93% | 57.50% | 57.60% | 30.04% | 19.30% | 13.11% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.